Pilot dose-ranging of rhIGF-1/rhIGFBP-3 in a preterm lamb model of evolving bronchopulmonary dysplasia.
Kurt H AlbertineMar Janna DahlAndrew RebentischElaine DawsonAkbar NabiSydney BowenCindy MiersZhengming WangHaixia YangBaifeng YuDonald M NullDennis KeefeJ-K ChungZ ZhouNorman BartonGalen CareyRobert WardPublished in: Pediatric research (2022)
Preterm birth is associated with rapid decreases in serum or plasma IGF-1 protein level. This decline adversely impacts the growth and development of the lung and cardiovascular system. For this pilot study, continuous infusion of optimal dosage of rhIGF-1/rhIGFBP-3 (1.5 mg/kg/day) to maintain physiologic plasma IGF-1 level of ~125 ng/mL during mechanical ventilation for 3 days statistically improved some structural and biochemical outcomes related to the alveolar formation that would favor improved gas exchange compared to vehicle-control. We conclude that 3 days of continuous iv infusion of rhIGF-1/rhIGFBP-3 improved some physiological, morphological, and biochemical outcomes, without toxicity, in mechanically ventilated preterm lambs.
Keyphrases
- preterm birth
- mechanical ventilation
- low birth weight
- gestational age
- acute respiratory distress syndrome
- intensive care unit
- binding protein
- low dose
- extracorporeal membrane oxygenation
- pi k akt
- type diabetes
- clinical trial
- study protocol
- respiratory failure
- randomized controlled trial
- insulin resistance
- small molecule
- weight loss
- drug induced
- double blind
- quantum dots